Beato’s Financials, Revenue, Profit, Valuation & Shareholding Overview (2025)
Legal Name: S3 Healthtech Private Limited | CIN: U74140DL2015PTC275512
Founded by Gautam Chopra, Yash Sehgal, and Kunal Kinalekar, BeatO is a leading digital health platform focused on diabetes management. BeatO combines connected devices, personalized health insights, and expert support to help individuals manage and reverse diabetes effectively. The company’s innovative app-based ecosystem integrates glucose monitoring, real-time data tracking, and coaching to deliver comprehensive care. With rapid growth across urban India and a strong focus on preventive health, BeatO is transforming how chronic lifestyle diseases are addressed. Backed by prominent investors and partnerships with major hospitals and insurers, BeatO continues to scale its operations and improve accessibility for millions of patients nationwide.
| Founded | 2015 |
|---|---|
| Headquarters | New Delhi, India |
| Valuation | ~$100 million |
| Annual Revenue (FY24 est.) | ₹110 Cr |
| Net Loss (FY24 est.) | ₹5 Cr |
| Employees | ~400 |
| Round | Year | Amount | Investors |
|---|---|---|---|
| Seed | 2017 | $1.5 million | Blume Ventures |
| Series A | 2019 | $5 million | Omidyar Network, others |
| Series B | 2022 | $33 million | Lightrock India, others |
BeatO has grown rapidly from ₹40 Cr in FY22 to ₹110 Cr in FY24, reflecting strong demand for its diabetes care solutions. Losses have narrowed significantly due to improved unit economics and scale benefits.
EBITDA margins improved from -50% in FY22 to -10% in FY24, supported by operational efficiencies and cost control measures, signaling a strong path toward profitability.
BeatO's team grew from 200 in FY22 to around 400 in FY24, supporting growth in technology, clinical operations, and customer care as the platform expands nationwide.
- Expand diabetic care solutions beyond metros into tier-2 and tier-3 cities
- Introduce new preventive healthcare services and device integrations
- Strengthen partnerships with hospitals and insurance providers
- Evaluate IPO potential post-2026 to support long-term scaling
BeatO recently announced partnerships with leading hospital chains to expand diabetes management services and secured additional funding to accelerate product development and market reach.
| Metric | Detail |
|---|---|
| Revenue FY24 | ₹110 Cr – Strong growth momentum |
| Net Loss FY24 | ₹5 Cr – Sharply reduced losses |
| EBITDA Margin | -10% – Moving towards breakeven |
| Valuation | ~$100M – Supported by strategic investors |
| Employees | ~400 – Strengthening operational capacity |
BeatO’s technology-driven approach to chronic disease management positions it as a future leader in digital health. With consistent revenue growth, improving margins, and strong partnerships, BeatO is on a clear path to scale further. Make smarter business decisions with verified insights on companies and directors. Visit Affluense.ai to learn more.
Economic Times, YourStory, Inc42, Company announcements
Disclaimer: © 2025. All information is curated from public and third-party sources and provided solely for legitimate business use.